Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTHSTAR phase 3 study of gildeuretinol acetate in Stargardt disease
2026-525296-60-00Phase 3Authorised
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Gildeuretinol acetate with Placebo (2 arms). Primary endpoint: Annualized growth rate of retinal atrophic lesions. Planned start Aug 2026; status: authorised.
02
Drugs
gildeuretinol
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2026-525296-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525296-60-00.